Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005425 | 0.91 | AR (0.39) | ARGRM2SLC6A4PGRSLC22A12 | |
| SCHEMBL30224570 | 0.78 | GRM2 (0.34) | ARGRM2SLC6A4MBOAT4 | |
| SCHEMBL23995539 | 0.76 | AR (0.48) | ARKDM1APGR | |
| SCHEMBL23993667 | 0.76 | SLC6A4 (0.41) | ARGRM2SLC6A4CHRM2CHRM1 | |
| SCHEMBL25004524 | 0.75 | SLC6A4 (0.38) | ARSLC6A4KDM1APGR | |
| SCHEMBL25006008 | 0.75 | TRPV4 (0.46) | ARSLC6A4KDM1A | |
| SCHEMBL25005998 | 0.75 | TSHR (0.41) | ARSLC6A4 | |
| SCHEMBL2665024 | 0.73 | AR (0.49) | ARGRM2MBOAT4SLC22A12 | |
| SCHEMBL21381847 | 0.72 | PDE4B (0.45) | AR | |
| SCHEMBL30149813 | 0.72 | PDE4B (0.45) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | AR 2789/4885GRM2 2198/4885SLC6A4 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.